📊 ELTP Key Takeaways
Is ELTP a Good Investment? Thesis Analysis
Elite Pharmaceuticals demonstrates exceptional financial health with robust profitability metrics (50.2% gross margin, 36.0% operating margin, 24.4% net margin) and strong revenue growth of 48.4% YoY. The company maintains fortress-like balance sheet strength with minimal leverage (0.02x debt/equity), exceptional liquidity (7.34x current ratio), and substantial free cash flow generation of $14.1M, providing strategic flexibility for growth initiatives.
Why Buy ELTP? Key Strengths
- Exceptional profitability with 50.2% gross margin and 36.0% operating margin indicating strong pricing power and operational efficiency
- Strong revenue growth of 48.4% YoY demonstrates robust market demand and successful commercialization
- Fortress balance sheet with minimal debt (0.02x debt/equity), $21.1M cash, and 7.34x current ratio providing financial flexibility
- Outstanding returns on equity (32.9%) and assets (20.9%) indicating efficient capital deployment
- Robust free cash flow of $14.1M with 13.0% FCF margin supporting sustainability of operations and potential reinvestment
ELTP Investment Risks to Consider
- Concerning EPS decline of -100% despite flat net income suggests significant equity dilution and share issuance
- Flat net income growth (0.0% YoY) despite 48.4% revenue growth indicates margin compression or one-time charges requiring investigation
- Limited insider activity with only 1 Form 4 filing in last 90 days suggests minimal insider confidence signals
- Pharmaceutical sector regulatory and patent cliff risks could impact future revenue sustainability and profitability
Key Metrics to Watch
- Net income growth trajectory relative to revenue growth to assess margin sustainability
- EPS recovery and share dilution trends to understand capital structure changes
- Free cash flow consistency and conversion from operating cash flow
- Gross margin stability amid competitive pricing pressures
- Debt levels and capital allocation decisions for shareholder returns
ELTP Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 7.34x current ratio provides a solid financial cushion.
ELTP Profitability Ratios
ELTP vs Healthcare Sector
How ELITE PHARMACEUTICALS INC /NV/ compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is ELTP Overvalued or Undervalued?
Based on fundamental analysis, ELITE PHARMACEUTICALS INC /NV/ appears fundamentally strong relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
ELTP Balance Sheet & Liquidity
ELTP 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: ELITE PHARMACEUTICALS INC /NV/'s revenue has grown significantly by 161% over the 5-year period, indicating strong business expansion. The most recent EPS of $0.02 reflects profitable operations.
ELTP Growth Metrics (YoY)
ELTP Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2026 | $14.4M | $615.8K | $-0.01 |
| Q2 2026 | $18.9M | $615.8K | $-0.01 |
| Q1 2026 | $18.8M | $615.8K | $0.00 |
| Q3 2025 | $14.4M | $615.8K | $0.00 |
| Q2 2025 | $14.2M | $615.8K | $0.01 |
| Q1 2025 | $9.0M | $615.8K | $0.00 |
| Q3 2024 | $9.3M | $305.9K | $0.00 |
| Q2 2024 | $8.6M | $305.9K | $0.00 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
ELTP Capital Allocation
ELTP SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for ELITE PHARMACEUTICALS INC /NV/ (CIK: 0001053369)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ELTP
What is the AI rating for ELTP?
ELITE PHARMACEUTICALS INC /NV/ (ELTP) has an AI rating of STRONG BUY with 85% confidence, based on fundamental analysis of SEC EDGAR filings.
What are ELTP's key strengths?
Claude: Exceptional profitability with 50.2% gross margin and 36.0% operating margin indicating strong pricing power and operational efficiency. Strong revenue growth of 48.4% YoY demonstrates robust market demand and successful commercialization.
What are the risks of investing in ELTP?
Claude: Concerning EPS decline of -100% despite flat net income suggests significant equity dilution and share issuance. Flat net income growth (0.0% YoY) despite 48.4% revenue growth indicates margin compression or one-time charges requiring investigation.
What is ELTP's revenue and growth?
ELITE PHARMACEUTICALS INC /NV/ reported revenue of $108.1M.
Does ELTP pay dividends?
ELITE PHARMACEUTICALS INC /NV/ does not currently pay dividends.
Where can I find ELTP SEC filings?
Official SEC filings for ELITE PHARMACEUTICALS INC /NV/ (CIK: 0001053369) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ELTP's EPS?
ELITE PHARMACEUTICALS INC /NV/ has a diluted EPS of $0.02.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is ELTP a good stock to buy right now?
Based on our AI fundamental analysis in March 2026, ELITE PHARMACEUTICALS INC /NV/ has a STRONG BUY rating with 85% confidence. The AI analysis suggests favorable fundamentals based on SEC filings. This is not investment advice.
Is ELTP stock overvalued or undervalued?
Valuation metrics for ELTP: ROE of 32.9% (sector avg: 15%), net margin of 24.4% (sector avg: 12%). Higher ROE suggests strong returns relative to peers.
Should I buy ELTP stock in 2026?
Our dual AI analysis gives ELITE PHARMACEUTICALS INC /NV/ a combined STRONG BUY rating for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is ELTP's free cash flow?
ELITE PHARMACEUTICALS INC /NV/'s operating cash flow is $14.6M, with capital expenditures of $527.6K. FCF margin is 13.0%.
How does ELTP compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 24.4% (avg: 12%), ROE 32.9% (avg: 15%), current ratio 7.34 (avg: 2).